สหภาพยุโรป -
ไอซ์แลนด์ -
EMA (European Medicines Agency)
senstend
plethora pharma solutions limited - lídókaín, prilocaine - Ótímabært sáðlát - svæfingarlyf - senstend er ætlað fyrir meðferð aðal ótímabært sáðlát í fullorðnum körlum.
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
ezetrol tafla 10 mg
n.v. organon* - ezetimibum inn - tafla - 10 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
ezetimibe alvogen (ezetimibe ratiopharm) tafla 10 mg
alvogen ehf. - ezetimibum inn - tafla - 10 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
ezetimib medical valley tafla 10 mg
medical valley invest ab - ezetimibum inn - tafla - 10 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
metvix krem 160 mg/g
galderma nordic ab - methyl aminolevulinate hydrochloride - krem - 160 mg/g
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
ezetimib krka tafla 10 mg
krka d.d. novo mesto* - ezetimibe - tafla - 10 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
singulair tuggutafla 4 mg
n.v. organon* - montelukastum natríum - tuggutafla - 4 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
vancomycin-mip innrennslisstofn, lausn 1000 mg
mip pharma gmbh - vancomycin hydrochloride - innrennslisstofn, lausn - 1000 mg
ไอซ์แลนด์ -
ไอซ์แลนด์ -
LYFJASTOFNUN (Icelandic Medicines Agency)
vancomycin-mip innrennslisstofn, lausn 500 mg
mip pharma gmbh - vancomycin hydrochloride - innrennslisstofn, lausn - 500 mg
สหภาพยุโรป -
ไอซ์แลนด์ -
EMA (European Medicines Agency)
farydak
pharmaand gmbh - vatnsfrí panóbínóstat laktat - mergæxli - Æxlishemjandi lyf - farydak, ásamt bortezomib og leiðbeina, er ætlað fyrir meðferð fullorðinn sjúklinga með fallið og/eða óviðráðanleg margar forráðamenn sem hafa fengið að minnsta kosti tvær áður en meðferð þar á meðal bortezomib og virkt efni. farydak, ásamt bortezomib og leiðbeina, er ætlað fyrir meðferð fullorðinn sjúklinga með fallið og/eða óviðráðanleg margar forráðamenn sem hafa fengið að minnsta kosti tvær áður en meðferð þar á meðal bortezomib og virkt efni.